# Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

> **NCT04088903** · PHASE1 · WITHDRAWN · sponsor: **Ronald Witteles**

## Conditions studied

- Allosensitization
- Heart Transplant Failure and Rejection

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04088903
- **Lead sponsor:** Ronald Witteles
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol changed to use subcutaneous rather than intravenous daratumumab.
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088903, "Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04088903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*